Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

COVID-19 vaccination, risk-compensatory behaviours, and contacts in the UK

Buckell J. et al, (2023), Scientific Reports, 13

Protection against SARS-CoV-2 Omicron BA.4/5 variant following booster vaccination or breakthrough infection in the UK

Wei J. et al, (2023), Nature Communications, 14

Data from Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

Rieunier G. et al, (2023)

Data from Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

Rieunier G. et al, (2023)

Supplementary Data from Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

Rieunier G. et al, (2023)

Supplementary Data from Targeting IGF Perturbs Global Replication through Ribonucleotide Reductase Dysfunction

Rieunier G. et al, (2023)

Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region

Emmenegger M. et al, (2023), iScience, 26, 105928 - 105928

Symptoms and Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Positivity in the General Population in the United Kingdom

Vihta KD. et al, (2022), Clinical Infectious Diseases, 75, e329 - e337

SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection

Wei J. et al, (2022), Nature Communications, 13

Automated 96-well format high throughput colony formation assay for siRNA library screen

Hatch SB. et al, (2022), STAR Protocols, 3, 101355 - 101355

Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines

Wei J. et al, (2022), Nature Medicine, 28, 1072 - 1082

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

Abani O. et al, (2022), The Lancet, 399, 665 - 676

CHK1 inhibition exacerbates replication stress induced by IGF blockade

Wu X. et al, (2022), Oncogene, 41, 476 - 488

Tracking the Emergence of SARS-CoV-2 Alpha Variant in the United Kingdom

Walker AS. et al, (2021), New England Journal of Medicine, 385, 2582 - 2585

Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs

Arnaiz E. et al, (2021), BMC Cancer, 21

Stringent thresholds in SARS-CoV-2 IgG assays lead to under-detection of mild infections

Eyre DW. et al, (2021), BMC Infectious Diseases, 21

Effect of Convalescent Plasma on Organ Support–Free Days in Critically Ill Patients With COVID-19

Abdelhady H. et al, (2021), JAMA, 326, 1690 - 1690

Anti-spike antibody response to natural SARS-CoV-2 infection in the general population

Wei J. et al, (2021), Nature Communications, 12

The Duration, Dynamics, and Determinants of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Responses in Individual Healthcare Workers

Lumley SF. et al, (2021), Clinical Infectious Diseases, 73, e699 - e709

Quantitative SARS-CoV-2 anti-spike responses to Pfizer-BioNTech and Oxford-AstraZeneca vaccines by previous infection status.

Eyre DW. et al, (2021), Clin Microbiol Infect

Load More

Include forthcoming?